Laurina

Desogestrel, the active ingredient in Laurina, is a combined oral contraceptive presented as an oral tablet for oral use. It works together with ethinylestradiol, an estrogen component, to provide reliable cycle control and contraceptive efficacy for women of reproductive age.

GNH USA supplies Laurina as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Laurina, a combined oral contraceptive, is used to prevent pregnancy by inhibiting ovulation and altering cervical mucus.

Contraception: prevents unintended pregnancy in women of childbearing potential. Menstrual regulation: helps establish a regular menstrual cycle and reduces dysmenorrhea. Acne management: improves acne associated with androgen excess in some patients.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Breast tenderness: temporary swelling or discomfort. - Headache: occasional mild to moderate pain. - Breakthrough bleeding: spotting between periods.

Serious or Rare Side Effects: - Venous thromboembolism: deep‑vein thrombosis or pulmonary embolism. - Arterial thrombosis: stroke or myocardial infarction. - Severe hypertension: sudden increase in blood pressure. - Allergic reactions: rash, swelling, or anaphylaxis.

Before starting Laurina, consider the following precautions: - Medical evaluation: assess personal and family history of thromboembolic disorders. - Smoking: avoid use if over 35 years old and a smoker. - Medication review: check for interacting drugs that may affect efficacy. - Pregnancy: discontinue immediately if pregnancy is confirmed. - Breastfeeding: discuss potential risks with a healthcare professional. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and light.

Laurina may interact with several medicines.

Major Interactions (Avoid): - Enzyme‑inducing antiepileptics (e.g., carbamazepine, phenytoin): markedly reduce contraceptive effectiveness. - St. John’s wort: decreases hormone levels, increasing risk of contraceptive failure. - Protease inhibitors (e.g., ritonavir): may elevate hormone concentrations and raise side‑effect risk.

Moderate Interactions (Monitor Closely): - Rifampin and other strong antibiotics: may lower efficacy, requiring cycle monitoring. - Azole antifungals (e.g., ketoconazole): can increase hormone levels, warranting observation for toxicity. - Selective serotonin reuptake inhibitors (e.g., fluoxetine): may affect hormone metabolism and require clinical vigilance.